SEC Info - Dr Reddys Laboratories Ltd - ‘6-K’ for 2/21/17

SEC Info℠

Home

Help

Please Sign In

Dr Reddys Laboratories Ltd – ‘6-K’ for 2/21/17 – ‘EX-99.2’

On: Tuesday, 2/21/17, at 8:01am ET · For: 2/21/17 · Accession #: 1193125-17-49409 · File #: 1-15182

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 2/21/17  Dr Reddys Laboratories Ltd        6-K         2/21/17    5:68K                                    Donnelley … Solutions/FA

Report by a Foreign Private Issuer — Form 6-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Report by a Foreign Private Issuer                  HTML     12K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML      7K 
 3: EX-99.2     Miscellaneous Exhibit                               HTML      7K 
 4: EX-99.3     Miscellaneous Exhibit                               HTML      8K 
 5: EX-99.4     Miscellaneous Exhibit                               HTML      7K

EX-99.2 — Miscellaneous Exhibit

This exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

EX-99.2

Exhibit 99.2

January 27, 2017


Listing Compliance		Listing Compliance
BSE Limited		National Stock Exchange of India Ltd.
Dalal Street, Fort		“Exchange Plaza”, Bandra-Kurla Complex,
Mumbai – 400 001		Bandra (East), Mumbai – 400 051
Fax Nos.: 022-22723121 / 22723719 /		Fax Nos.: 022-26598120/ 26598237/
22722037 / 22722039		26598238

Scrip Code: 500124		Scrip Code: DRREDDY-EQ

Dear Sirs,

Ref.:

Your email dated January 27, 2017.

Sub:

Clarification on media release in the Financial Express dated January 26, 2017 – Korean biotech firm Mezzion Pharma files suit against Dr. Reddy’s Laboratories.

This is with reference to your email dated January 27, 2017, seeking clarification about the news item which appeared in ‘The Financial Express’ dated January 26, 2017, captioned ‘Korean biotech firm Mezzion Pharma files suit against Dr. Reddy’s Laboratories.’

‘In this regard, we would like to state that a company who used to be a customer of Dr. Reddy’s – Mezzion Pharma issued a press note of their own in Korea stating that they have filed a suit against Dr. Reddy’s. As of now, the Company has not been served with any legal papers or legal process in the matter referred to in Mezzion’s press release.’

With regards,

Sandeep Poddar

Company Secretary

CC:- New York Stock Exchange Inc.(Stock Code: RDY)

Dates Referenced Herein

This ‘6-K’ Filing	Date	Other Filings

Filed on / For Period End:	2/21/17	None on these Dates
	1/27/17
	1/26/17
		List all Filings

↑Top

Filing Submission 0001193125-17-049409 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)